Application of chicoric acid in preparation of medicine for treating salpingitis
By using chicorylic acid to inhibit fallopian tube inflammation and cell necrosis, activate the Nrf2 signaling pathway, and regulate the Notch pathway, the problem of insufficient effectiveness in treating fallopian tubeitis is solved, and significant therapeutic effects are achieved and side effects are avoided.
Patent Information
- Application Number
- CN202411033476.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-08
AI Technical Summary
Existing drugs are not effective in treating fallopianitis, especially in chronic inflammation or the presence of adhesions and pus accumulation. The treatment cycle is long, the dosage is large, and it is easy to develop drug resistance, and it is easy to cause a variety of side effects and is prone to recurrence.
Using chicolic acid as an active ingredient, by inhibiting the oxidative stress response, inflammatory response and cell necrosis apoptosis of fallopian tube tissue, activates the Nrf2 signaling pathway, regulates the Notch pathway, and alleviates the hydrocele, pus and hematoma of the fallopian tube, and uses it as The main preparation is treated.
It significantly reduces fallopian tube inflammation, inhibits cell necrosis, improves fallopian tube function, and avoids intensifying inflammatory response. Its efficacy is comparable to that of the fluoroquinolonone antibiotic moxifloxacin, but it avoids its common side effects.
Smart Images

Figure CN118903093A_ABST
Abstract
Description
Technical Field
[0001] The invention specifically relates to the use of chicoric acid in preparing medicine for treating salpingitis. Background Art
[0002] Salpingitis is a common gynecological clinical disease, which is divided into acute and chronic salpingitis according to the different causes of the disease. Hypertrophy of the fallopian tubes and hydrosalpinx caused by chronic salpingitis are one of the important causes of female infertility. The cause of salpingitis is the upward spread of infection from inflammation of the lower reproductive tract, which may present as chronic inflammatory changes due to inappropriate and incomplete treatment. Although antibiotics and other anti-inflammatory drugs can be used to control acute inflammation, for chronic inflammation or situations where adhesions and pus have already formed, relying solely on drug treatment is often ineffective. In addition, the existing drug treatment cycle is long, the dosage is large, and it is easy to develop drug resistance, which causes a variety of side effects and is prone to recurrence.
[0003] Cichoric acid is a caffeic acid derivative, mainly found in natural plants such as Echinacea, chicory, and Pulsatilla. It is also called inulin acid, a polysaccharide compound formed by acid carboxylation of inulin molecules. It has a colorless to light yellow solid form and is soluble in water and alcohol. It is now widely used in food, medicine, and animal husbandry products.
[0004] Pharmacological studies in recent years have shown that chicoric acid has antioxidant, immune-enhancing, antiviral, blood sugar-lowering, liver-protecting, uric acid-lowering, and anti-atherosclerotic effects. Due to its significant biological activity and pharmacological effects, it has shown potential in modern medical research, but there is currently no research on its application in gynecological diseases, especially in the treatment of salpingitis. Summary of the invention
[0005] In order to solve the above problems, the present invention provides the use of chicoric acid in preparing a drug for treating salpingitis
[0006] Furthermore, the drug is a drug for inhibiting the oxidative stress response of fallopian tube inflammation tissue.
[0007] Furthermore, the drug is a drug for alleviating the inflammatory response of salpingitis tissue.
[0008] Furthermore, the drug is a drug for inhibiting necroptosis of cells in salpingitis tissue.
[0009] Furthermore, the drug is a drug that inhibits necroptosis of fallopian tube tissue cells by activating the Nrf2 signaling pathway and regulating the Notch pathway.
[0010] Furthermore, the medicine is a medicine for alleviating pathological damage of salpingitis tissue.
[0011] Furthermore, the medicine is a medicine for improving hydrosalpinx, abscess and hematoma.
[0012] Furthermore, the drug is a preparation prepared with chicoric acid as an active ingredient and pharmaceutically acceptable excipients.
[0013] Furthermore, the preparation includes an oral preparation.
[0014] The invention discloses a method for preparing a medicine for treating salpingitis using chicoric acid. The invention provides a method ...
[0015] Obviously, according to the above contents of the present invention, in accordance with common technical knowledge and customary means in the art, without departing from the above basic technical ideas of the present invention, other various forms of modification, replacement or change may be made.
[0016] The above contents of the present invention are further described in detail below through specific implementation methods in the form of embodiments. However, this should not be understood as the scope of the above subject matter of the present invention being limited to the following examples. All technologies realized based on the above contents of the present invention belong to the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1(A) H&E staining to evaluate tubal injury (n=4). Blue arrows indicate cytolysis; black arrows represent inflammatory cells; green arrows indicate tubal hemorrhage; (B) Histopathological score of tubal injury; (C) IL-1β; (D) TNF-α; (E) IL-6; (F) Collagen fibers were determined and quantified by Masson staining. Sham sham group, Salpingitis salpingitis group, CA chicoric acid control group, CAL chicoric acid low-dose group, CAH chicoric acid high-dose group, MFX moxifloxacin group, statistical data are expressed as mean ± SEM (n=7). *P<0.05, ****P<0.0001, * indicates comparison with Sham group; ##P<0.01, ###P<0.001, ####P<0.0001, # indicates comparison with Salpingitis group; @@P<0.01, @ indicates comparison with CAH group.
[0018] Figure 2 (A) Transmission electron microscopy observation of changes in oviduct epithelial organelles. Blue arrows indicate mitochondrial membrane wrinkling and increased mitochondrial membrane density; yellow arrows indicate swollen lysosomes; red arrows indicate ciliary rupture; (B) CAT; (C) GSH; (D) LDH; (E) MDA. Sham sham group, Salpingitis salpingitis group, CA chicoric acid control group, CA L chicoric acid low-dose group, CA H chicoric acid high-dose group, MFX moxifloxacin group, statistical data are expressed as mean ± SEM (n = 7). ***P < 0.001, ****P < 0.0001, * indicates comparison with Sham group; #P < 0.05, ##P < 0.01, ###P < 0.001, # indicates comparison with Salpingitis group; @P < 0.05, @ indicates comparison with CAH group.
[0019] Figure 3 (A) Western blotting analysis of RIPK1, RIPK3, p-MLKL and MLKL; (B) Immunofluorescence staining showed the effect of chicoric acid on RIPK3 level. (C) Immunohistochemical expression analysis of RIPK3. Sham sham group, Salpingitis salpingitis group, CA chicoric acid control group, CA L chicoric acid low-dose group, CAH chicoric acid high-dose group, statistical data are expressed as mean ± SEM (n = 7). ***P < 0.001, ****P < 0.0001, * indicates comparison with Sham group; #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001, # indicates comparison with Salpingitis group; @P < 0.05, @@@@P < 0.0001, @ indicates comparison with CA H group.
[0020] Figure 4 (A) Western blotting analysis of Notch1, NICD, and Hes-1; (B) Immunofluorescence staining showed the effect of chicoric acid on Notch1 levels. (C) Immunohistochemical expression analysis of Notch1. Sham sham group, Salpingitis salpingitis group, CA chicoric acid control group, CA L chicoric acid low-dose group, CA H chicoric acid high-dose group, statistical data are expressed as mean ± SEM (n = 7). ****P < 0.0001, * indicates comparison with Sham group; ##P < 0.01, ####P < 0.0001, # indicates comparison with Salpingitis group; @@@P < 0.001, @@@@P < 0.0001, @ indicates comparison with CA H group.
[0021] Figure 5 (A) Western blotting analysis of Nrf2; (B) Immunofluorescence staining showed the effect of chicoric acid on Nrf2 level. (C) Immunohistochemical expression analysis of Nrf2. Sham sham group, Salpingitis salpingitis group, CA chicoric acid control group, CA L chicoric acid low-dose group, CAH chicoric acid high-dose group, statistical data are expressed as mean ± SEM (n = 7). ****P < 0.0001, * indicates comparison with Sham group; #P < 0.05, ##P < 0.01, ###P < 0.001, # indicates comparison with Salpingitis group; @@@P < 0.001, @@@@P < 0.0001, @ indicates comparison with CA H group.
[0022] Figure 6 (A) Appearance of fallopian tube; (B) H&E staining to evaluate fallopian tube damage (n=4). Blue arrows indicate cytolysis; black arrows represent inflammatory cells; green arrows indicate tubal bleeding; (C) Histopathological score of fallopian tube damage. Salpingitis group, CAH high-dose chicoric acid group, DAPT high-dose chicoric acid + DAPT group, ML385 high-dose chicoric acid + ML385 group, statistical data are expressed as mean ± SEM (n=7). @@@P<0.001, @ indicates comparison with CA H group.
[0023] Figure 7(A) Western blotting analysis of Nrf2, Notch1, and RIPK3; (B) Immunofluorescence staining showed the effect of chicoric acid on the levels of Nrf2, Notch1, and RIPK3; (C) Immunohistochemical expression analysis of Nrf2, Notch1, and RIPK3; (D) Transmission electron microscopy observation of changes in fallopian tube epithelial organelles, blue arrows indicate mitochondrial membrane wrinkling and increased mitochondrial membrane density; yellow arrows indicate swollen lysosomes; red arrows indicate cilia rupture. Salpingitis salpingitis group, CA H chicoric acid high-dose group, DAPT chicoric acid high-dose + DAPT group, ML385 chicoric acid high-dose + ML385 group, statistical data are expressed as mean ± SEM (n = 7). ###P<0.001, # indicates comparison with Salpingitis group; @@P<0.01, @@@P<0.001, @@@@P<0.0001, @ indicates comparison with CA H group. DETAILED DESCRIPTION
[0024] The raw materials, equipment and reagents used in the specific implementation of the present invention are all known products, which are obtained by purchasing commercially available products. Among them, chicoric acid is provided by Chengdu Mansite Company (item number A0409, HPLC>98%).
[0025] Example 1 Study on the application of chicoric acid in improving salpingitis
[0026] 1. Experimental methods
[0027] 1.1 Experimental animals
[0028] SD rats, 8 weeks old, were kept in an animal room at 20-26°C, relative humidity 30%-70%, 12h light per day, day and night cycle, free access to food and water. The experiment started after 1 week of adaptive feeding.
[0029] Method for establishing the animal model of salpingitis: dilute the stock solutions of the three bacteria to 3×10 ^9 CFU / L. Escherichia coli, Staphylococcus aureus and β-hemolytic Streptococcus were then mixed in a volume ratio of 2:1:1 to form a standby bacterial suspension. Rats were anesthetized by intraperitoneal injection of 3% sodium pentobarbital and then placed in a supine position. After skin disinfection, a 1 cm midline incision was made to enter the abdominal cavity and expose the uterus. After identifying the bilateral fallopian tubes according to the Y-shaped uterine position, 0.05 ml of the reagent was injected into the bilateral fallopian tubes at the uterine-fallopian tube junction. The skin layer and muscle were then sutured, and iodine was applied to disinfect the surgical site. Finally, the rats were placed on a constant temperature blanket until they were fully resuscitated.
[0030] Sham surgery model establishment method: rats were anesthetized by intraperitoneal injection of 3% sodium pentobarbital and then placed in a supine position. After skin disinfection, a 1 cm midline incision was made to enter the abdominal cavity and expose the uterus. After identifying the bilateral fallopian tubes according to the Y-shaped uterine position, 0.05 ml of PBS was injected into the bilateral fallopian tubes at the uterine-fallopian tube junction. The skin layer and muscles were then sutured, and iodine was applied to disinfect the surgical site. Finally, the rats were placed on a constant temperature blanket until they were fully resuscitated.
[0031] 1.2 Grouping and Dosing
[0032] In the first stage, SD rats were divided into 6 groups (10 in each group) by random number table method: sham operation group, salpingitis group, chicoric acid control group, low-dose chicoric acid group, high-dose chicoric acid group and moxifloxacin group. Since some drugs with anti-inflammatory effects, such as non-steroidal anti-inflammatory drugs and glucocorticoids, cannot effectively treat salpingitis, moxifloxacin, which is commonly used in the clinical treatment of salpingitis, was used as a positive control to verify the effectiveness of this method. After a 4-week recovery period after modeling, each group received a daily designated dose of the drug for 4 weeks. The rats used in the salpingitis group, low-dose chicoric acid group, high-dose chicoric acid group and moxifloxacin group were salpingitis rats, and the sham operation group and chicoric acid control group were sham operation rats. The low and high doses of chicoric acid were 10 mg / kg and 30 mg / kg, respectively, dissolved in 1 ml of normal saline for oral gavage; the dose of moxifloxacin was 42 mg / kg, dissolved in 1 ml of normal saline for oral gavage. The sham operation group and the salpingitis group were gavaged with 1 mL of normal saline. The experiment ended four weeks after administration, and the rats were anesthetized and euthanized.
[0033] In the second phase of the experiment, SD rats were divided into 4 groups (10 rats in each group) using a random number table method: salpingitis group, high-dose chicoric acid group, DAPT group, and ML385 group. DAPT is a specific inhibitor of the notch pathway, and ML385 is a specific inhibitor of Nrf2. The doses of DAPT (10 mg / kg, intraperitoneal injection) and ML385 (10 mg / kg, intraperitoneal injection) were based on relevant literature. After the salpingitis model was established, rats in the DAPT group and ML385 group were given DAPT / ML385 1 hour before the administration of chicoric acid. The remaining groups were treated with the same administration method as in the first phase. Subsequently, all rats were anesthetized and euthanized after the end of the in vivo experiment.
[0034] 1.3 Observation indicators
[0035] 1.3.1 General condition of rats
[0036] Hair color, mental state, food and water intake, and daily activities were recorded. The rat body weight was recorded weekly until the end of the experiment. In addition, the appearance, color, adhesion, elasticity, and thickness of the oviduct and surrounding tissues were directly observed.
[0037] 1.3.2 Pathological damage
[0038] HE staining: After anesthesia, the fallopian tubes were collected, rinsed with PBS, fixed with 4% paraformaldehyde, dehydrated with gradient ethanol solution, then embedded in paraffin and cut into 4μm thick sections. The sections were stained with hematoxylin-eosin and observed under a light microscope. The specific scoring criteria for fallopian tube damage are as follows:
[0039] Expansion degree: no obvious expansion = 0; mild expansion of a single cross section = 1; expansion of 2-3 cross sections = 2; expansion of more than 3 cross sections = 3; confluent and obvious expansion = 4. Inflammatory infiltration: no obvious inflammatory cell infiltration = 0; single lesion infiltration = 1; infiltration of 2-4 lesions = 3; infiltration of more than 4 lesions = 3; confluent infiltration = 4.
[0040] Masson staining: The embedded paraffin tissue was sliced and then dewaxed using a gradient of xylene and ethanol-water. The slices were stained with Weigert's iron hematoxylin for 10 minutes, followed by staining with Ponceau acid fuchsin staining solution for 30 seconds and then rinsed. The slices were differentiated in a phosphotungstic acid solution for 15 minutes, stained with aniline blue solution for 5 minutes, and immersed in a 0.2% glacial acetic acid solution for 1 minute. Finally, the slices were dehydrated with alcohol, transparentized with xylene, and sealed with neutral gum. Image acquisition and analysis were performed under an optical microscope.
[0041] TNF-α, IL-1β, IL-6: After anesthesia, the abdominal cavity was exposed, and blood samples were collected from the abdominal aorta with a blood collection needle. The collected blood was precipitated for 2 hours and then centrifuged at 3000 rpm for 10 minutes at 4°C to separate the upper serum. Subsequently, the supernatant was divided into multiple centrifuge tubes and stored in a -80°C freezer. Serum TNF-α, IL-1β, and IL-6 levels were quantitatively detected using commercially available ELISA kits according to the manufacturer's instructions.
[0042] MDA, CAT, GSH, LDH: The right oviduct of each group of rats was taken, rinsed with saline and dried with gauze. The tissue was then homogenized and centrifuged at 12,000 rpm for 10 minutes at 4°C, and the supernatant was collected. The total protein concentration was quantified using a BCA protein assay kit. Subsequently, the levels of MDA, CAT, GSH, and LDH in the oviduct tissue were determined according to the manufacturer's instructions.
[0043] Electron microscopy: The left oviduct of the rat was removed after anesthesia, pre-fixed in 3% glutaraldehyde, and then fixed in 1% osmium tetroxide. Then it was dehydrated using a series of acetone gradients, embedded in epoxy resin, and ultrathinly sectioned, stained with lead citrate and uranyl acetate. Images were collected using a JEM-1400Flash transmission electron microscope.
[0044] Immunofluorescence: The fallopian tube tissue was embedded in paraffin, sliced into 5 μm slices, and mounted on slides. Subsequently, the slices were incubated at 60°C for 2 hours, dewaxed with xylene and hydrated with gradient ethanol. The tissue sections were then placed in a repair box containing citric acid antigen retrieval buffer and antigen retrieval was performed in a microwave oven. After rinsing with PBS, 3% hydrogen peroxide was treated for 30 minutes to inhibit endogenous peroxidase activity. After washing with PBS three times again, the slides were blocked in PBS with 3% bovine serum albumin at 37°C for 1 hour, and then the primary antibody was dropped and incubated overnight at 4°C. Finally, the sections were incubated with secondary antibodies at room temperature for 1 hour, the cell nuclei were counterstained with DAPI, anti-fluorescence quenching solution was added to seal the slides, and observed under a microscope.
[0045] Immunoblotting: The fallopian tube tissue was collected, frozen in liquid nitrogen and stored at -80°C for further analysis. After the tissue was sheared and added to the lysis buffer, the tissue was homogenized with a mechanical homogenizer for 30 seconds, and then centrifuged at 12,000 g for 10 minutes to collect the resulting supernatant. The protein was detected by 6-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The protein was then transferred to a PVDF membrane and incubated with 5% bovine serum albumin or 5% skim milk. After blocking, the primary antibody was incubated overnight. The next day, the secondary antibody was incubated at room temperature. Finally, the chemiluminescent substrate ECL was used to observe the protein bands.
[0046] Immunohistochemistry: Tissue sections were dewaxed with xylene and then hydrated through graded ethanol. Subsequently, antigen extraction was performed on the sections in sodium citrate buffer using an autoclave. The slides were then washed three times by immersion in PBS. After drying the sections, circles were drawn around the tissue to prevent antibody diffusion. Bovine serum albumin was then added dropwise, and after blocking, the primary antibody was added and incubated overnight at 4°C. The next day, the secondary antibody was added and incubated for 30 minutes, and the color developer diaminobenzidine was used for staining. Harris hematoxylin staining was used for counterstaining. The sections were then dehydrated, blocked, and images were acquired and analyzed using a microscope.
[0047] 2. Experimental results
[0048] 2.1 Results of the first phase of experiments
[0049] 2.1.1 General condition of rats
[0050] After modeling, rats in the sham operation group and the chicoric acid control group showed normal spirit and appetite, smooth fur, and agile activities. However, rats in the salpingitis group, the low-dose chicoric acid group, the high-dose chicoric acid group, and the moxifloxacin group showed symptoms of drowsiness, decreased activity, dull and unkempt fur, and decreased appetite after modeling. These results indicate that the model was successfully constructed.
[0051] After 4 weeks of intervention with chicoric acid and moxifloxacin, the general condition of the rats improved. The symptoms of mental depression, decreased activity, and dull skin in the rats in the high-dose chicoric acid group and the moxifloxacin group were significantly improved. After the model was established, the weight of the rats in the salpingitis group gradually increased, and the weight gain of the rats in the high-dose chicoric acid group and the moxifloxacin group was more obvious than that in the salpingitis group. In addition, the presence of mixed bacterial infection led to pathological changes in the fallopian tube. Among them, the fallopian tubes in the sham operation group and the chicoric acid control group had a uniform appearance, smooth and rounded shape, consistent elasticity, and no obvious signs of hydrosalpinx and bilateral pyosalpinx. The fallopian tubes in the salpingitis group showed pathological changes: the diameter of the fallopian tubes was irregular and the surface was rough. In addition, hematomas were observed in the fallopian tubes connecting the two ovaries. After the administration of chicoric acid, the appearance of the fallopian tubes (hydrosalpinx, pus, and hematoma) in the rats was significantly improved compared with the salpingitis group, and it was dose-dependent. Moxifloxacin treatment also showed an improvement effect similar to that of the high-dose chicoric acid group. These findings demonstrate the potential efficacy of chicoric acid in the treatment of salpingitis.
[0052] 2.1.2 Pathological damage
[0053] HE staining ( Figure 1 A) shows that the mucosa, muscularis, and serosa structures of the fallopian tube tissue in the sham operation group and the chicoric acid control group were intact, and no obvious pathological changes were observed. The fallopian tube mucosa of rats in the salpingitis group was inflammatory and edematous, with inflammatory cell infiltration, mainly distributed in the fallopian tube stroma and ciliated cells. In the fallopian tube inflammation group, local mucosal epithelial cells in the fallopian tube were necrotic, the cell nuclei were condensed and fragmented, the mucosa was mildly congested, and the cytoplasm was dissolved. However, from a pathophysiological point of view, the effect of low-dose chicoric acid in the treatment of salpingitis is poor. In the low-dose chicoric acid group, the fallopian tube mucosal epithelial cells were necrotic and sloughed, inflammatory cells infiltrated, and the cytoplasm was dissolved. Similar to the moxifloxacin group, high-dose chicoric acid reduced the pathological damage of the fallopian tube tissue and reduced the histopathological score of fallopian tube damage (Tables 1-2, Figure 1 B).
[0054] Table 1 Histopathological score of fallopian tube injury 1
[0055] Group A Group B Group C Group D Group E Group F Sham Salpingitis CA CA L H MXF 0 8 1 8 6 6 0 7 0 6 4 5 1 6 1 6 5 5 1 7 0 5 5 4 0 6 0 6 4 4 0 7 1 7 4 5 0 8 0 7 5 6
[0056] Table 2 Mean and mean difference of pathological scores of fallopian tube injury tissue
[0057] name Average 1 Average 2 Mean Difference Sham vs. Salpingitis 0.2857 7.000 -6.714 Sham vs. CA 0.2857 0.4286 -0.1429 Sham vs. CA L 0.2857 6.429 -6.143 Sham vs. CA H 0.2857 4.714 -4.429 Sham vs. MXF 0.2857 5.000 -4.714 Salpingitis vs. CA 7.000 0.4286 6.571 Salpingitis vs. CA L 7.000 6.429 0.5714 Salpingitis vs. CA H 7.000 4.714 2.286 Salpingitis vs. MXF 7.000 5.000 2.000 CA vs. CA L 0.4286 6.429 -6.000 CA vs. CA H 0.4286 4.714 -4.286 CA vs.MXF 0.4286 5.000 -4.571 CA L vs. CAH 6.429 4.714 1.714 CA L vs.MXF 6.429 5.000 1.429
[0058] Masson staining ( Figure 1F) shows that in Masson staining, the fallopian tube inflammation group showed obvious structural abnormalities, aggravated fibrosis, and increased collagen fiber levels. This observation suggests that fibrosis changes occurred after 8 weeks of modeling. The number of blue-stained collagen fibers in each dose group of chicoric acid was significantly reduced compared with the model group, in a dose-dependent manner. This suggests that chicoric acid has a protective effect on the fallopian tubes of rats with fallopian tube inflammation.
[0059] TNF-α, IL-1β, IL-6 expression levels ( Figure 1 CE) showed that the levels of TNF-α, IL-1β and IL-6 were increased in the salpingitis group. In contrast, the levels of TNF-α, IL-1β and IL-6 in the chicoric acid group decreased in a dose-dependent manner.
[0060] Transmission electron microscopy ( Figure 2 A) Findings: The sham and CA groups had abundant and complete cilia, normal cilia morphology, regular arrangement of cilia, and typical microtubule structures. The mitochondria and endoplasmic reticulum structures were clear, and the endoplasmic reticulum was neatly and densely arranged without dilation and vesicles. In the salpingitis group, cilia and microvilli were arranged in disorder, mitochondrial membranes were wrinkled, endoplasmic reticulum was dilated, and there were more autophagic lysosomes. Interestingly, cell organelle swelling and cytoplasmic lysis, which are signs of necroptosis, were also observed by electron microscopy, and chicoric acid administration reversed the changes in cell ultrastructure.
[0061] MDA, CAT, GSH, LDH expression levels ( Figure 2 BE) showed that mixed bacterial infection in the fallopian tubes resulted in increased levels of malondialdehyde (MDA) and lactate dehydrogenase (LDH), and decreased levels of catalase (CAT) and glutathione (GSH). After administration of chicoric acid, MDA and LDH levels decreased, and CAT and GSH levels increased. These findings confirm the antioxidant properties of chicoric acid in rats with fallopian tube inflammation.
[0062] Western blot detection ( Figure 3 A) Expression of necroptosis-related key proteins RIPK1, RIPK3, p-MLKL, and MLKL. The expression of RIPK1, RIPK3, and p-MLKL was increased in the salpingitis group, but this trend was alleviated by chicoric acid administration in a dose-dependent manner. Immunofluorescence and immunohistochemistry were then used to detect ( Figure 3 BC) RIPK3 expression. Immunofluorescence and immunohistochemistry analysis revealed that RIPK3 levels were decreased after chicoric acid treatment, which was consistent with the results of Western blot. These results provide additional evidence for the role of chicoric acid in inhibiting necroptosis in salpingitis.
[0063] To further clarify the mechanism of action of chicoric acid, the expression of Notch1, NICD and Hes-1 proteins in the fallopian tube was analyzed to verify the effect of chicoric acid on the Notch1 signaling pathway ( Figure 4 A). Mixed bacterial infection of the fallopian tubes induced activation of the Notch1 signaling pathway, leading to increased levels of Notch1, NICD, and Hes-1 proteins. The expression of Notch1, NICD, and Hes-1 was decreased in both the low-dose and high-dose chicoric acid groups. Consistent with the results of western blot analysis, immunohistochemical staining and immunofluorescence ( Figure 4 The same trend was also observed in BC, where the expression level of Notch1 was lower in the chicoric acid-treated group compared with the salpingitis group. This confirms that the protective mechanism of chicoric acid against salpingitis may be related to the inhibition of the Notch1 signaling pathway.
[0064] Given that chicoric acid has an antioxidant effect on salpingitis, western blot was used to detect the expression of the key antioxidant protein Nrf2 ( Figure 5 A). Nrf2 levels were significantly decreased in the salpingitis group compared with the sham group, and chicoric acid administration reversed this change, especially in the high-dose group. To confirm these findings, immunohistochemistry and immunofluorescence staining techniques were used ( Figure 5 BC). The results suggest that Nrf2 expression was enhanced after chicoric acid administration in both the low-dose and high-dose chicoric acid groups. These observations suggest that chicoric acid may alleviate salpingitis by activating Nrf2 signaling.
[0065] 2.2 Results of the Second Phase Experiment
[0066] Based on the results of the first phase of the experiment, the Nrf2 inhibitor ML385 and the Notch1 inhibitor DAPT were used to explore the regulatory role of the Nrf2 / Notch1 axis in salpingitis. After Notch1 was inhibited in the DAPT group, the uneven diameter, irregular appearance, and rough surface of the fallopian tubes were reduced. In contrast, inhibition of Nrf2 reversed the therapeutic effect of chicoric acid on salpingitis ( Figure 6 A).
[0067] Histological analysis with HE staining showed Figure 6 B): Compared with the high-dose chicoric acid group, DAPT inhibition of Notch1 reduced the degree of inflammatory damage in the fallopian tube, although the histopathological score did not reach statistical significance. The results of HE staining showed that ( Figure 6B-C, Tables 3-4). The use of ML385 weakened the therapeutic effect of chicoric acid on salpingitis. Necrosis occurred in local mucosal epithelial cells. The mucosa in the ML385 group was mildly congested, with cytoplasmic lysis and inflammatory cell infiltration. Compared with the salpingitis group, the administration of ML385 resulted in similar tubal damage. These findings suggest that the Nrf2 / Notch1 axis plays a crucial role in the pathogenesis of salpingitis, and chicoric acid may treat salpingitis by regulating the Nrf2 / Notch1 axis.
[0068] Table 3 Histopathological score of fallopian tube injury 2
[0069] Group A Group B Group C Group D H DAPT ML385 Salpingitis 5 5 8 7 6 5 6 6 4 3 7 8 5 3 8 7 6 5 8 7 5 4 7 7 4 3 7 8
[0070] Table 4 Mean and mean difference of pathological score 2 of fallopian tube injury tissue
[0071]
[0072] To further investigate the role of Nrf2 / Notch1 axis in the treatment of salpingitis, the effect of Nrf2 / Notch1 axis on necroptosis in rats with salpingitis was detected. Western blotting analysis showed that ( Figure 7 A), DAPT treatment resulted in decreased levels of Notch1 and RIPK3, whereas Nrf2 expression was unaffected compared with the high-dose chicoric acid group. ML385 could inhibit the upregulation of Nrf2 and downregulation of Notch1 and RIPK3 induced by chicoric acid. It is speculated that Notch1, as a downstream effector protein of the Nrf2 signaling pathway, is regulated by Nrf2. The protein expression trends observed in the ML385 group were very similar to those in the salpingitis group, suggesting that inhibition of Nrf2 attenuated the efficacy of chicoric acid in the treatment of salpingitis.
[0073] Consistent with the western blot results, immunofluorescence and immunohistochemistry staining ( Figure 7 BC) showed decreased expression levels of Notch1 and RIPK3 in the DAPT group, while ML385 counteracted the upregulation of Nrf2 and downregulation of Notch1 and RIPK3 induced by chicoric acid, respectively. The DAPT group showed milder programmed cell necrosis with minimal organelle swelling compared with the high-dose chicoric acid group. In contrast, ML385 reversed the anti-necroptotic effect of chicoric acid in salpingitis, resulting in ER dilation, organelle swelling, cristae membrane rupture, and cell disintegration ( Figure 7 D). Chicoric acid may reduce programmed necrosis, alleviate pathological damage of the fallopian tube in rats, improve hydrosalpinx, pus and hematoma, and play a role in treating salpingitis by activating the Nrf2 signaling pathway and inhibiting the Notch1 pathway.
[0074] The above experimental results confirmed that chicoric acid plays a protective role in salpingitis by reducing the levels of TNF-α, IL-1β, and IL-6, reducing the levels of MDA and LDH in salpingitis tissues, increasing the levels of CAT and GSH, alleviating inflammatory responses, and inhibiting oxidative stress responses. In addition, chicoric acid can activate the Nrf2 signaling pathway, thereby regulating the Notch pathway and inhibiting necroptosis of fallopian tube cells, thereby improving hydrosalpinx, pus, and hematoma. The application of ML385 and DAPT confirmed that the Nrf2 / Notch1 axis is involved in the therapeutic effect of chicoric acid on salpingitis. The therapeutic effect of chicoric acid on rats with salpingitis is related to the inhibition of necroptosis of fallopian tube cells through the Nrf2 / Notch1 axis.
[0075] In summary, the chicoric acid of the present invention inhibits the inflammatory reaction of the salpingitis tissue, the oxidative stress reaction, plays a protective role on the fallopian tube tissue, and by activating the Nrf2 signaling pathway, the Notch pathway is regulated to inhibit the necroptosis of the fallopian tube cells, thereby avoiding the aggravation of the inflammatory reaction, improving the hydrosalpinx, pus and hematoma of the fallopian tube. A two-pronged approach is adopted from the symptoms and the cause of the disease, reducing the pathological damage of the fallopian tube, playing a significant role in treating salpingitis, and the curative effect is comparable to the fluoroquinolone antibiotic moxifloxacin commonly used in the clinic. The application of chicoric acid in the treatment of salpingitis has a good clinical application prospect.
Claims
1. Use of chicoric acid in the preparation of drugs for treating salpingitis 2. The use according to claim 1, characterized in that: The medicine is a medicine for inhibiting the oxidative stress response of fallopian tube inflammation tissue.
3. The use according to claim 1, characterized in that: The medicine is a medicine for alleviating the inflammatory response of fallopian tube inflammation tissue.
4. The use according to claim 1, characterized in that: The medicine is a medicine for inhibiting necrosis and apoptosis of cells in fallopian tube inflammation tissue.
5. The use according to claim 4, characterized in that: The drug is a drug that inhibits necroptosis of fallopian tube tissue cells by activating the Nrf2 signaling pathway and regulating the Notch pathway.
6. The use according to claim 1, characterized in that: The medicine is a medicine for alleviating pathological damage of salpingitis tissue.
7. The use according to any one of claims 1 to 6, characterized in that: The medicine is a medicine for improving hydrosalpinx, abscess and hematoma of the fallopian tube.
8. The use according to claim 1, characterized in that: The medicine is a preparation prepared by taking chicoric acid as an active ingredient and adding pharmaceutically acceptable auxiliary materials.
9. The use according to claim 8, characterized in that: The preparations include oral preparations.
Citation Information
Cited By
Application of chicoric acid in preparation of medicine for preventing or treating bad pregnancy outcome
CN119792266A
